High Level of Pretreatment and Acquired Human Immunodeficiency Virus Drug Resistance in El Salvador: A Nationally Representative Survey, 2018-2019.
Central America
El Salvador
HIV
WHO
drug resistance surveillance
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
29
08
2022
accepted:
31
10
2022
entrez:
28
11
2022
pubmed:
29
11
2022
medline:
29
11
2022
Statut:
epublish
Résumé
Human immunodeficiency virus drug resistance (HIVDR) can negatively impact the effectiveness of antiretroviral therapy (ART). We aimed to estimate the prevalence of pretreatment HIVDR (PDR) among ART initiators and the prevalence of viral load (VL) suppression and acquired HIVDR among individuals receiving ART for 12 ± 3 months (ADR12) and ≥48 months (ADR48) in El Salvador. Nationally representative cross-sectional PDR, ADR12 and ADR48 surveys were conducted among adults with HIV from October 2018 to August 2019, following World Health Organization-recommended methods. Demographic and clinic data and blood specimens were collected. Two hundred sixty participants were enrolled in the PDR survey, 230 in ADR12 and 425 in ADR48. Twenty-seven percent (95% confidence interval [CI], 17.1%-39.9%) of ART initiators had PDR to efavirenz or nevirapine. The prevalence of VL suppression was 88.8% (95% CI, 83.1%-92.8%) in ADR12 and 80.5% (95% CI, 76.6%-84.0%) in ADR48 surveys. Among people with HIV receiving a first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART regimens and with unsuppressed VL, the prevalence of ADR to efavirenz or nevirapine was 72.0% (95% CI, 32.3%-93.3%) and 95.0% (68.5%-99.4%) in the ADR12 and ADR28 surveys, respectively. ADR12 to boosted protease inhibitors (PI/r) or integrase strand transfer inhibitors (INSTIs) was not observed. ADR48 was 1.3% (95% CI, 0.2%-9.6%) and 2.1% (0.3%-13.7%), respectively. Programmatic improvements in ART delivery are urgently needed in El Salvador to address the high levels of resistance to efavirenz or nevirapine among ART initiators and the low VL suppression prevalence among individuals on treatment.
Sections du résumé
Background
UNASSIGNED
Human immunodeficiency virus drug resistance (HIVDR) can negatively impact the effectiveness of antiretroviral therapy (ART). We aimed to estimate the prevalence of pretreatment HIVDR (PDR) among ART initiators and the prevalence of viral load (VL) suppression and acquired HIVDR among individuals receiving ART for 12 ± 3 months (ADR12) and ≥48 months (ADR48) in El Salvador.
Methods
UNASSIGNED
Nationally representative cross-sectional PDR, ADR12 and ADR48 surveys were conducted among adults with HIV from October 2018 to August 2019, following World Health Organization-recommended methods. Demographic and clinic data and blood specimens were collected.
Results
UNASSIGNED
Two hundred sixty participants were enrolled in the PDR survey, 230 in ADR12 and 425 in ADR48. Twenty-seven percent (95% confidence interval [CI], 17.1%-39.9%) of ART initiators had PDR to efavirenz or nevirapine. The prevalence of VL suppression was 88.8% (95% CI, 83.1%-92.8%) in ADR12 and 80.5% (95% CI, 76.6%-84.0%) in ADR48 surveys. Among people with HIV receiving a first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART regimens and with unsuppressed VL, the prevalence of ADR to efavirenz or nevirapine was 72.0% (95% CI, 32.3%-93.3%) and 95.0% (68.5%-99.4%) in the ADR12 and ADR28 surveys, respectively. ADR12 to boosted protease inhibitors (PI/r) or integrase strand transfer inhibitors (INSTIs) was not observed. ADR48 was 1.3% (95% CI, 0.2%-9.6%) and 2.1% (0.3%-13.7%), respectively.
Conclusions
UNASSIGNED
Programmatic improvements in ART delivery are urgently needed in El Salvador to address the high levels of resistance to efavirenz or nevirapine among ART initiators and the low VL suppression prevalence among individuals on treatment.
Identifiants
pubmed: 36438615
doi: 10.1093/ofid/ofac580
pii: ofac580
pmc: PMC9685178
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac580Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. The authors: No reported conflicts of interest.
Références
J Int AIDS Soc. 2019 Dec;22(12):e25429
pubmed: 31860167
AIDS Behav. 2017 Jun;21(6):1755-1767
pubmed: 27582088
J Virol Methods. 2008 Nov;153(2):176-81
pubmed: 18706932
Clin Microbiol Infect. 2013 Dec;19(12):E523-32
pubmed: 23782115
J Infect Dis. 2017 May 1;215(9):1362-1365
pubmed: 28329236
J Antimicrob Chemother. 2016 Oct;71(10):2918-27
pubmed: 27342546
J Antimicrob Chemother. 2017 Feb;72(2):504-510
pubmed: 27789684
Lancet Infect Dis. 2018 Mar;18(3):346-355
pubmed: 29198909
J Int AIDS Soc. 2019 Nov;22(11):e25415
pubmed: 31746541
Mol Biol Evol. 2013 Dec;30(12):2725-9
pubmed: 24132122
PLoS One. 2019 Sep 3;14(9):e0221879
pubmed: 31479466
J Antimicrob Chemother. 2018 Jul 1;73(7):1965-1971
pubmed: 29608685
J Antimicrob Chemother. 2020 Mar 1;75(3):656-667
pubmed: 31819984
J Infect Dis. 2017 Dec 1;216(suppl_9):S801-S804
pubmed: 29040686
Lancet Infect Dis. 2009 Jul;9(7):409-17
pubmed: 19555900
PLoS Med. 2016 Nov 29;13(11):e1002183
pubmed: 27898679
J Infect Dis. 2009 Sep 1;200(5):687-97
pubmed: 19604043
PLoS One. 2019 Aug 28;14(8):e0220337
pubmed: 31461455
J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):23-31
pubmed: 21694603
Clin Infect Dis. 2019 Oct 15;69(9):1498-1505
pubmed: 30601976
Lancet HIV. 2017 Dec;4(12):e547-e554
pubmed: 29107562
AIDS Res Hum Retroviruses. 1995 Nov;11(11):1413-6
pubmed: 8573400
J Antimicrob Chemother. 2020 Jul 1;75(7):1932-1942
pubmed: 32303063
J Antimicrob Chemother. 2017 Nov 01;72(11):3149-3158
pubmed: 28961972
HIV Med. 2017 May;18(5):342-353
pubmed: 27704659
J Med Virol. 2012 Oct;84(10):1514-21
pubmed: 22930496
J Clin Microbiol. 2012 Jun;50(6):1936-42
pubmed: 22403431
J Int AIDS Soc. 2018 Oct;21(10):e25194
pubmed: 30350392
Lancet Infect Dis. 2019 Mar;19(3):253-264
pubmed: 30732940
J Antimicrob Chemother. 2019 Apr 1;74(4):1044-1055
pubmed: 30597094
Mol Biol Evol. 2018 Jul 1;35(7):1812-1819
pubmed: 29401317
Clin Infect Dis. 2006 Jun 1;42(11):1608-18
pubmed: 16652319
Nucleic Acids Res. 2003 Jan 1;31(1):298-303
pubmed: 12520007
J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):74-8
pubmed: 23774877
Infect Genet Evol. 2013 Oct;19:337-48
pubmed: 23660484